Merus N.V.

Based on the opinions of our employees, we’ve been recognized as a World Class Workplace for 2022. This label is awarded by our employee listening partner, Effectory, and was founded to celebrate organizations who are dedicated to their people. Thanks to everyone at Merus who makes our organization a great place to work. #CloseInOnCancer

At Merus, we work towards discovering and developing new treatments for cancer. Every day, we bring a sense of urgency and a passion to help patients with #HNSCC, #NSCLC, #PDAC, and other types of cancer. Time is of the essence. #CloseInOnCancer https://merus.nl/

Merus announces first patient dosed in phase 2 trial of petosemtamab in 2L CRC.  #CloseInOnCancer https://lnkd.in/eNzJp6Dc

Welcoming Dr. Fabian Zohren as our new Chief Medical Officer. Bringing late-stage clinical development expertise to our team, Dr. Zohren will play a key role in the initiation of our two randomized phase 3 trials, planned to start later this year. #CloseInOnCancer

Please join us in welcoming Haley as our summer intern. She comes to us from Elon University where she’s majoring in strategic communications. Happy to have you aboard! #CloseInOnCancer

What is the optimal way to detect pathogenic gene fusions like NRG1? Benjamin Weinberg, MD, highlights the advantages of RNA-based next generation sequencing and how it can capture what other tests might miss. Watch the video at bit.ly/4bHTrKJ  #PrecisionOncology #FindTheFusions #PrecisionMedicine

Bill Lundberg, MD, Merus’ CEO, will participate in a fireside chat today at the Jeffries Global Healthcare Conference. The live webcast will be available on our Investors page and for a limited time thereafter. #JefferiesHealthcare #CloseInOnCancer

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at #ASCO24 #CloseInOnCancer

NRG1 tumors are associated with aggressive features and poor outcomes. Find out more about the threat of NRG1 tumors at FindTheFusions.com #PrecisionOncology #FindTheFusions #PrecisionMedicine.

We are excited to share the interim clinical data presented on petosemtamab in combination with pembrolizumab in first line #HNSCC at #ASCO24, with a 67% response rate per investigator. See the full presentation with safety and efficacy from a 3/6/24 cutoff. https://lnkd.in/eQHsHRBf